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Corneal limbal stem cell deficiency (LSCD) may be treated using ex vivo limbal epithelial stem cells (LESCs) derived from
cadaveric donor tissue. However, continuing challenges exist around tissue availability, inflammation, and transplant rejection.
Lipopolysaccharide (LPS) or recombinant human IL-1𝛽 stimulated primary human keratocyte and LESC models were used to
investigate the anti-inflammatory properties of a short chain, IL-1 receptor antagonist peptide for use in LESC sheet growth to
control inflammation. The peptide was characterized using mass spectroscopy and high performance liquid chromatography.
Peptide cytotoxicity, patterns of cell cytokine expression in response to LPS or IL-1𝛽 stimulation, and peptide suppression of
this response were investigated by MTS/LDH assays, ELISA, and q-PCR. Cell differences in LPS stimulated toll-like receptor 4
expression were investigated using immunocytochemistry. A significant reduction in rIL-1𝛽 stimulated inflammatory cytokine
production occurred following LESC and keratocyte incubation with anti-inflammatory peptide and in LPS stimulated IL-6 and
IL-8 production following keratocyte incubation with peptide (1mg/mL) (𝑃 < 0.05). LESCs produced no cytokine response to LPS
stimulation and showed no TLR4 expression. The peptide supported LESC growth when adhered to a silicone hydrogel contact
lens indicating potential use in improved LESC grafting through suppression of inflammation.
1. Introduction
Approximately 4.9 million people worldwide are bilaterally
blind due to corneal opacity and corneal blindness is the
fifth most common cause of blindness globally [1]. The
restoration of a healthy limbal epithelial stem cell fraction is
vital to the treatment of corneal blindness associated with the
breakdown of corneal epithelial integrity. Limbal epithelial
stem cells (LESCs) are located in the basal region of the
limbus, where the corneal epithelium meets the sclera, and
are important in maintaining the structural integrity and
transparency of the cornea [2]. LESCs are responsible for
maintenance of corneal epithelial integrity through provision
of a continuously renewed corneal epithelium, by producing
a steady supply of daughter transient amplifying cells which
differentiate into basal, wing, and squamous epithelial cells
[3]. Cells move in an inwardly spiraling pattern from the
basal to apical layers of the epithelium where the squamous
cells at the surface of the cornea are continuously lost into
the tear film. LESCs may be destroyed by injury (chemi-
cal burns, contact lens-induced keratopathy), infection or
disease (aniridia, Stevens-Johnson syndrome, and ocular
cicatricialpemphigoid) [4–7] resulting in a condition known
as limbal epithelial stem cell deficiency (LSCD). When this
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occurs, conjunctival epithelial overgrowth, vascularisation,
and chronic inflammation may result in scarring and the loss
of corneal transparency.
Therapeutic replacement of corneal limbal epithelial stem
cells is an ongoing area of investigation. In the UK, the
most widely used surgical therapy to treat LSCD is the
use of cadaveric-derived LESC cultures which are grown
to confluency and then transplanted using an amnion ban-
dage. The use of cadaveric tissue is thought to reduce the
risk of tissue rejection since a number of human leuko-
cyte antigen-DR (HLA-DR) expressing Langerhans cells are
significantly reduced following 14 days of storage [8, 9].
However, immunosuppressant drugs are still required after
treatment and the rate of LESC allograft failure after 6months
is approximately 27% and is often associated with chronic
inflammation [10–12].
Current techniques to control inflammation rely on the
use of anti-inflammatory drugs or amniotic membrane.
Amnion is used as both a bandage and as a LESC sheet carrier
membrane and is thought to possess anti-inflammatory
properties. Although the exact mechanisms are unknown,
amniotic membrane-derived epithelial cells have been shown
to express IL-1 receptor antagonist (IL-1ra) [13] and corneal
epithelial cells cultured on amniotic membrane produced
reduced quantities of IL-1 [14]. IL-1 is known to instigate
corneal inflammation and angiogenesis so that suppression
of its activity may facilitate graft integration. The amniotic
membrane is thought to provide a favourable microenvi-
ronment for LESC similar to the corneal limbus [15, 16].
However, the use of anti-inflammatory drugs and amnion is
associated with significant clinical risk including interdonor
variability, increased risk of infection, and corneal melting
[17]. Amniotic membrane is derived from the inner placenta
and, like other tissues used in transplantation, carries a risk
of viral pathogen transmission [18–20]. Furthermore, the
application of amniotic membrane in clinic requires the use
of sutures or fibrin glue, which introduces additional risk
of infection and irritation [21, 22]. Corneal calcification,
linked to the use of amnion in conjunction with eye drops
after surgery, can also result in corneal clouding caused
by insoluble deposits and further surgery is often required.
Such issues highlight the benefit of developing alternative
approaches to the management of inflammation which
utilises the positive aspects of amnion function without the
negative side effects of amnion use. Other carrier materials,
including fibrin matrices, Mebiol gel polymers, recombinant
human cross-linked collagen scaffolds, collagen gel, keratin
film, silk fibroin, and temperature-responsive polymers, have
been investigated as amnion substitutes [23–30]. However,
none of these has been widely used in the clinical setting and
long-term clinical outcomes remain unknown.
Key issues therefore remain in the control of inflamma-
tion and in the optimisation of cell carrier technology for
use in the transport and application of cell grafts. The aim
of this study was to develop an anti-inflammatory peptide
which can be combined with a carrier matrix to facilitate
cell grafting and concurrently reduce inflammation. Here we
report the synthesis and characterisation of a short sequence
IL-1 beta antagonist peptide as an anti-inflammatory amnion
biomimic. Using a cell model of corneal inflammation, we
show a reduction in proinflammatory cytokines IL-6 and IL-8
with the peptide when cells are stimulated with LPS or IL-1𝛽.
Use of a short chain rather than full length peptide improves
the potential for conformational binding of active peptide
to a carrier surface. We further show that the peptide can
be conjugated to a commercially available silicon hydrogel
contact lens, while maintaining corneal limbal stem cell
growth.
2. Materials and Methods
All reagents were purchased from Sigma-Aldrich, UK, unless
stated otherwise.
2.1. Synthesis of the IL-1 Receptor Antagonist Peptide and
Isolation and Growth of Primary Corneal Epithelial Cells and
Keratocyte Cell Strains for Cell Assays. The study utilised
an IL-1 receptor antagonist (ra) peptide first identified
by Yanofsky et al. [31] and Vigers et al. [32] with NCBI
reference AF10847 and primary sequence of COOH–
LPLAYPQWYYANSEEWTFPTE–NH
2
. Peptide chain
assembly was carried out using solid phase peptide synthesis
with Fmoc protected amino acid derivatives built onto a
TentaGelS NH
2
resin bead support (Novabiochem, Iris
Biotech GMBH). Repeated cycles of Fmoc deprotection
and amide bond coupling were carried out using single
N-protected amino acids followed by a final cleavage step to
release the peptide sequence from the resin support.
The yield and purity of the peptide were examined using
mass spectrometry and high performance liquid chromatog-
raphy (HPLC). Mass spectrometry was carried out using a
BrukerDaltronicsMicrOTOF time-of-flight spectrometer set
with a spray voltage of −4.5 KV, end point offset of −500V,
nebulizer gas pressure at 0.4 bar, dry gas at 4 L/min, and
dry temperature of 180∘C using a mass to charge ratio of 50
to 3000 m/z. HPLC was carried out using a Phenomenex
C18 column stationary phase with mobile phase HPLC grade
water and acetonitrile gradient settings of water : acetonitrile
0.1min 95% : 5%, 30min 30% : 70%, 5min 0 : 100%, and 2min
95% : 5% and a flow rate of 0.8mL/min.
All in vitro cell assays were carried out using donor
tissue derived corneal cell strains in order to produce an
isolated biological testing environment which more closely
modelled the in vivo setting. Corneal tissue was obtained
from MEH Lions Eye Bank, Moorfields Eye Hospital under
ethics approval REC number 06/Q1907/81 using approved
informed consent procedures for the use of human tissue
in medical research. All ocular tissues were collected as
corneoscleral rims.
For epithelial cell isolation, tissue sections of approx-
imately 1mm were removed from the limbal rings at the
corneal/conjunctival junction and cut into small pieces prior
to dissociation of cells in 0.5% trypsin (Gibco, UK) at 37∘C
for 40 minutes. Trypsin was inactivated by the addition of
media and cells were centrifuged for 4 minutes at 400G.
The cell pellet was resuspended in media and cultured in
25 cm2 culture flasks or 24 well plates as required (Greiner
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Bio-One, UK). Cells were cultured at 37∘C, 5% CO
2
using
R&G complete growth medium containing DMEM and
Ham’s F12medium (Life Technologies, UK) at a 3 : 1 ratio, 10%
heat inactivated foetal calf serum (FCS, GE Healthcare, UK),
10 ng/mL epidermal growth factor (EGF, Life Technologies,
UK), 0.4mg/mL hydrocortisone, and 10 nM cholera toxin on
a feeder layer of lethally gamma-irradiated 3T3 feeder cells (2
× 104 3T3s per cm2) [33].
For keratocyte isolation, stromal tissue was dissected
into small pieces and placed into 25 cm2 flasks. Stromal
explants were incubated overnight at 37∘C, 5% CO
2
to allow
attachment to the flask surface, and then submerged in
DMEM supplemented with 10% FCS. All cells were grown
until subconfluent and media were replaced every two to
three days.
2.2. Assessment of Peptide Cytotoxicity Using MTS and
LDH Assays. Cell viability was measured using the CytoTox
96 nonradioactive cytotoxicity assay and the CellTiter 96
AQueous one solution cell proliferation assay (Promega, UK).
Primary human keratocytes were used for these assays since
these were more readily available than the LESCs. Cells were
seeded into 96 well plates at 2.5 × 104 cells per well and
left to attach for 24 hours prior to addition of peptide in
a range of concentrations from 0.01 to 1000mg/mL for 24
hours. Analysis of cell proliferation and cytotoxicity was
carried out according to manufacturer’s standard protocols.
1% v/v Triton-Xwas used as a positive control. Gram-negative
bacterial lipopolysaccharide (LPS from Serratia marcescens)
was also assessed for cytotoxic effects using concentrations
from 0.002 to 200mg/mL.
2.3. Peptide Inhibition of Inflammatory Cytokine Production
by Keratocytes and LESC. Infection and inflammation were
assessed using isolated human keratocyte and LESC strains.
Cells were stimulated with LPS to imitate cell response
to bacterial infection and with IL-1𝛽 to imitate corneal
inflammatory response, in which constitutively expressed
and upregulated IL-1𝛽 is released into the extracellular space
and underlying stroma following tissue damage. LPS and IL-
1𝛽 stimulation of cytokines IL-8, IL-6, and IL-1𝛽 by corneal
epithelial cells and keratocyte primary cell strains and the
impact of IL-1ra peptide activity on this response were
assessed.
Cytokine production by keratocytes in response to a
range of concentrations of LPS (0–200𝜇g/mL) and IL-1𝛽 (0
to 1 × 10−9M, BD Biosciences, UK) was assessed in order
to establish optimum concentrations to study the effect of
the peptide. As availability of large stocks of LESC cultures
was limited, studies using LESC were only performed using
the optimum concentrations identified in experiments using
keratocyte cultures (0.02 𝜇g/mL LPS and 1 × 10−9M IL-1𝛽).
Keratocytes at a concentration of 2 × 104 cells were seeded
into the wells of 96 well plates and allowed to attach for 6
hours. LESCs isolated from corneoscleral rims were seeded
into the wells of 24 well plates and allowed to grow until
subconfluent over 2 weeks. Cells were then incubated for
24 hours in serum-free medium spiked with LPS or IL-1𝛽.
1% Triton-X, LPS/IL-1𝛽 only, and medium only groups were
used as controls. Cell supernatants were collected and stored
at −80∘C prior to carrying out cytokine ELISAs according
to manufacturer’s instructions and using sample dilutions of
1 : 300 (IL-8/IL-6) and 1 : 10 (IL-1𝛽) (BD Biosciences).
2.4. Keratocyte Expression of IL-1𝛽 mRNA following LPS
Stimulation. Since no IL-1𝛽 protein was detected following
stimulation of keratocytes with LPS, mRNA expression was
assessed. Keratocytes (5 × 104 cells per well) were cultured in
24 well plates for 6 hours prior to treatment in either medium
only, 0.02 𝜇g/mL LPS, or 0.02𝜇g/mL LPS plus 1mg/mL
peptide for 24 hours. RNA was extracted using a Qiagen
RNeasy kit (Qiagen, Germany) and q-PCR was carried out
using a Bio-Rad iScript cDNA synthesis kit (Bio-Rad, UK)
and a Qiagen Rotor-Gene Q Pure Detection Machine to
assess expression of IL-1𝛽 using isoform specific primer sets
(Alta Biosciences,UK) [14]. All q-PCR assayswere performed
according to the MIQE guidelines [34].
2.5. Immunocytochemical Assessment of TLR4 Expression
by Keratocyte and LESC Cultures. Since LPS stimulation
induced upregulation of cytokine production by keratocytes
and not by LESCs, the presence of TLR4 LPS receptors
was assessed. Cells were cultured on 13mm diameter cover
slips, fixed with 3% v/v formaldehyde for 15 minutes, and
permeabilized in perm/quench solution (50mM ammonium
chloride, 0.2% saponin) for 15 minutes. Cell were incubated
in mouse anti-human TLR4 monoclonal antibody (AbCam,
UK) diluted 1 : 50 in PGAS (0.2% gelatin from cold water
fish skin, 0.02% saponin in PBS) for 1 hour in a humidified
chamber followed by incubation with FITC conjugated goat
anti-mouse IgG secondary antibody (AbCam, UK) diluted
1 : 100 in PGAS for 30 minutes at room temperature. Cov-
erslips were mounted in Antifade Gold with DAPI reagent
(Life Technologies, UK) and images were captured on a Zeiss
Axioscope fluorescentmicroscope usingAxioVision software
(Zeiss Ltd, Germany). Secondary antibody only controls were
used to assess primary antibody specificity.
2.6. Surface Modification, Functionalization, and Peptide
Binding to Contact Lens. Silicon hydrogel based contact lens
(Bausch & Lomb, UK) were surface modified with amine
(NH
2
) groups. Each contact lens was submerged in 20% 3-
aminopropyltriethoxysilane (APTES) for 15 minutes, washed
in toluene and methanol, and then air-dried. The number
of NH
2
groups present on the functionalised contact lens
surface was quantified using a methyl orange assay. Lenses
were placed in the wells of a 24-well plate and incubated in
methyl orange (476 𝜇M) at room temperature for 2 hours.
Each lens was washed with 10mM sodium phosphate, dried,
and submerged in ethanol to remove any methyl orange
bound to the lens. 100 𝜇L of this solution was transferred to
a 96-well plate and absorbance was read at 490 nm using an
ASYS UVH 340 plate reader. Concentrations were calculated
using a standard curve of methyl orange ranging from 0 to
476 𝜇M. Since the methyl orange binds to NH
2
groups with a
1 : 1 ratio, the concentration of methyl orange is proportional
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Figure 1: (a) Crude products from the synthesis of the IL-1ra analogue peptide (2606Da) were analysed by mass spectrometry. Component
intensity is shown on the 𝑦-axis in arbitrary units. Prominent peaks are atm/z 1303 (2+) and 869 (3+) and correspond to the original peptide
molecular weight. (b) HPLC chromatogram of crude products from the synthesis of IL-1ra analogue peptide (MW2606Da) indicated a single
prominent peak at 15-minute retention time.
to the concentration of amine groups [35]. Nontreated lenses
were used as controls.
The peptide carboxyl groups were cross-linked to the
amine groups on the surface of each contact lens using
5mM N-hydroxysuccinimide (NHS) and 2mM 1-ethyl-3-
(3󸀠-dimethylaminopropyl)carbodiimide (EDC) prepared by
dilution in 4-morpholinoethanesulfonic acid (MES) buffer
(0.1M of MES and 0.3M of NaCl, pH 7). 1-2mg peptide
and 1mL EDC/NHS buffer were incubated for 15 minutes at
room temperature, added to the modified contact lens, and
incubated for 2 hours at room temperature. Unbound peptide
was removed by rinsing in PBS.
Successful binding of the peptide to the contact lens
was measured using the bicinchoninic acid (BCA, Thermo
Scientific, UK) assay. Peptide conjugated contact lenses were
submerged in 300 𝜇L of 50 : 1 BCA/copper (II) sulphate
solution and incubated at 37∘C for 45 minutes. 200𝜇L
of the solution was transferred to a clean 96-well plate
and absorbance was read at 562 nm. Concentrations of the
peptide were calculated by comparison with a standard curve
of known peptide concentrations. Nontreated lenses were
included as controls.
2.7. Growth of LESC on Peptide-Conjugated Silicon Lenses.
Corneal epithelial cells freshly isolated from 3 separate
donors were seeded directly onto the peptide-conjugated
contact lenses and comparedwith cells seeded onto glass cov-
erslips. Cells were cultured in R&G medium and the pheno-
type of the cells was confirmed using immunocytochemical
staining for K3 (Millipore, USA), K19 (Dako, UK), and p63
(Millipore, USA) (all at 1 : 50 dilution in PGAS) using the
same method as described for TLR4 immunocytochemical
staining in 2.5. K3 was used to identify corneal epithelial cells
and K19 and p63 were used as putative markers of limbal
epithelial stem cell fraction. Alexa Fluor 488 Phalloidin (Life
Technologies, UK) (1mg/mL in PBS) was used to observe
cell structure. Secondary antibody only controls were used to
assess primary antibody specificity.
2.8. Statistical Analysis. All experiments were performed
with cells from at least three different donors. For statistical
analysis, ANOVA all-pairwise comparison using the Holm-
Sidak method was performed using SigmaStat (Systat, USA).
3. Results
3.1. Synthesis and Analysis of an IL-1 Receptor Antagonist
Peptide. Successful synthesis of the peptide was confirmed
by MS and HPLC. Two prominent peaks were observed on
the mass spectrum of the synthesised peptide. The most
abundant peak was at m/z of 1303 (2+) and the second was
at 869 (3+) corresponding with the correct molecular weight
of the peptide at 2606Da.TheHPLC chromatogram of crude
products from the synthesis of the peptide revealed a peak
with retention time of 15 minutes indicating a purity yield of
88% (Figures 1(a) and 1(b)).
3.2. Assessment of Peptide Cytotoxicity Using MTS and LDH
Assays. The peptide was not cytotoxic to keratocytes at
a concentration range of up to 1000 𝜇g/mL and had no
significant effect on cell viability (Figure 2) (𝑃 < 0.01,
𝑛 = 3). LPS was not cytotoxic to keratocytes but induced a
significant reduction in cell viability to 80%at a concentration
of 200𝜇g/mL.
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Figure 2: (a) LDH was measured to assess the cytotoxic effect of keratocyte treatment with increasing concentrations of peptide (0.01–
1000 𝜇g/mL). (b) MTS conversion to formazan was measured to assess peptide impact on keratocyte metabolism treated as in (a). No
significant difference was shown in peptide treated groups compared to nontreated controls (𝑃 > 0.05) (𝑛 = 3, mean ± sd).
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Figure 3: IL-6 and IL-8 production by keratocytes in response to increasing concentrations of LPS. LPS (0.02–200 𝜇g/mL) induced a
significant rise in (a) IL-8 and (b) IL-6 secretion by keratocytes when compared to the non-LPS treated controls (∗∗𝑃 < 0.01). In both
assays controls of Triton-X and 0.02 𝜇g/mL LPS (no cells) were included (𝑛 = 6, mean ± sd).
3.3. Peptide Inhibition of Inflammatory Cytokine Production
by Corneal Cells Stimulated with LPS or IL-1𝛽. Keratocytes
secreted up to 20 ng/mL IL-8 following stimulation with
LPS at a concentration range of 0.02 to 20mg/mL and
up to 75 ng/mL IL-6 following stimulation with 0.02 to
200mg/mL (Figure 3). Keratocytes did not secrete detectable
IL-1𝛽 in response to LPS stimulation. Addition of peptide at
concentrations ranging from 1 ng/mL to 1000𝜇g/mL induced
a significant decrease in production of IL-8 and IL-6 to
negligible levels at the highest concentration of 1000𝜇g/mL
(Figure 4). Stimulation of LESC with LPS did not yield any
detectable IL-8, IL-6, or IL-1𝛽 secretion.
When keratocytes were stimulated with recombinant
IL-1𝛽 the addition of the peptide at a concentration of
1000 𝜇g/mL resulted in a statistically significant decrease
in IL-8 and IL-6 (𝑃 < 0.01) (Figures 5(a) and 5(b)).
A significant reduction in IL-1𝛽 levels occurred when
the peptide was added at a concentration of 0.01𝜇g/mL,
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Figure 4: Peptide suppression of IL-6 and IL-8 production by LPS-stimulated keratocytes. (a) IL-8 and (b) IL-6 were secreted by keratocytes
when stimulatedwith 0.02 𝜇g/mLLPS and a range of peptide concentrations (0.001–1000 𝜇g/mL).The addition of 1000 𝜇g/mLpeptide resulted
in a significant reduction in cytokine secretion (∗∗𝑃 < 0.01). (𝑛 = 6, mean ± sd). Peptide (1000 𝜇g/mL) with no cells, peptide (1000𝜇g/mL)
and LPS (0.02 𝜇g/mL) without cells, and Triton-X and cells were included as controls.
while a significant increase was observed at 1000𝜇g/mL
(Figure 5(c)). Keratocytes are known to upregulate IL-1𝛽 via
an autocrine loop and a number of different stimuli so that
the IL-1𝛽 response to peptide inhibition does not follow
the same pattern of inhibition as for IL-6 and IL8 [36–38].
After stimulation of LESCwith IL-1𝛽, addition of 1000 𝜇g/mL
peptide resulted in a significant reduction in IL-8, IL-6, and
IL-1𝛽 levels (Figure 6).
These results show that the IL-1ra peptide analogue was
able to inhibit the production of proinflammatory cytokines
IL-6, IL-8, and IL-1𝛽 in both LESC and keratocytes following
stimulation with recombinant IL-1𝛽 and was able to inhibit
the production of IL-6 and IL-8 by keratocytes following LPS
stimulation.
3.4. Keratocyte Expression of IL-1𝛽 mRNA following LPS
Stimulation. Although IL-1𝛽 secretion by keratocytes could
not be detected by ELISA following LPS stimulation, a
significant increase in IL-1𝛽mRNA levels was detected by q-
PCR. This was significantly reduced when 1mg/mL peptide
was added (Figure 7) indicating that LPS and peptide do have
an effect on IL-1𝛽 levels in keratocytes, although levelsmay be
below the detection limit of ELISA.
3.5. Immunocytochemical Assessment of TLR4 Expression
by Keratocyte and LESC Cultures. Since LPS stimulation
resulted in cytokine upregulation in keratocytes but not in
LESC, the presence of toll-like receptor 4 (TLR4), which
mediates LPS activity, was assessed by immunocytochem-
istry. TLR4 could be readily detected in the cytoplasm of
permeabilized keratocytes, indicating a cytoplasmic pool of
the protein, as well as on the plasma membrane of non-
permeabilized cells, further indicating active TLR-4 receptor
(Figure 8). However, no staining could be detected in the
cytoplasm or cell membrane of LESC explaining the lack of
cytokine upregulation by LPS in LESC.
3.6. Surface Modification, Functionalization, and Peptide
Binding to Contact Lens. Successful functionalization of the
lens surfaces with NH
2
groups was required for peptide
binding and was confirmed using methyl orange. Treatment
with APTE and methyl orange resulted in distinctive orange
colouration, indicating the presence of NH
2
groups, whilst
untreated lenses remained colourless (Figure 9(a)). An aver-
age NH
2
binding of 66.5 nmol was observed through calcu-
lation of methyl orange at a 1 : 1 binding ratio of dye to NH
2
groups. The BCA assay was used to measure the amount of
peptide bound to the contact lens surface. Lenses treated with
APTES and peptide stained purple indicating the presence of
peptide. Untreated lenses remained colourless (Figure 9(b)).
Adding 1000 𝜇g/mL (115 nM) peptide to the APTES treated
lenses resulted in average binding of 2.7 nmol peptide.
Increasing the peptide concentration did not increase the
amount of peptide bound to the contact lens indicating that
the NH
2
groups on the surface are the limiting factor.
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Figure 5: Peptide suppression of cytokine production by IL-1𝛽 stimulated keratocytes. (a) IL-8 and (b) IL-6 secretion by keratocytes
stimulated with IL-1𝛽 (10−9M) and a range of peptide concentrations (0.001–1000𝜇g/mL) was significantly reduced following addition of
1000 𝜇g/mL peptide when compared to the group containing no peptide (∗∗𝑃 < 0.01). (c) IL-1𝛽 secretion by keratocytes stimulated with
IL-1𝛽 (10−9M) and a range of peptide concentrations (0.001–1000𝜇g/mL) showed significant differences in cytokine secretion at 0.01𝜇g/mL
and 1000𝜇g/mL (∗∗𝑃 < 0.01) compared to the no peptide added controls (𝑛 = 3, mean ± sd).
3.7. Growth of LESCs on Peptide-Conjugated Lenses. LESCs
were successfully cultured on the inner surface of the peptide
modified contact lens without affecting LESC morphology
and phenotype compared to cells grown on glass coverslips
(Figures 10(a) and 10(b)). Phalloidin stain showed character-
istic epithelial morphology. The presence of LESC markers
cytokeratin 3 (K3), cytokeratin 19 (K19), and p63 further
confirmed normal LESC phenotype.
4. Discussion
IL-1 is considered to be a “master” cytokine in the eye, due
to its involvement in the initial response to injury or insult
[39] as well as its ability to stimulate the production of
other proinflammatory cytokines [40, 41].Themechanism of
action of IL-1 is key to inflammatory responses in the eye,
facilitated by its constitutive expression by corneal epithelial
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Figure 6: Peptide suppression of cytokine production by IL-1𝛽 stimulated LESC. (a) IL-8, (b) IL-6, and (c) IL-1𝛽 secretion by LESC when
stimulated with IL-1𝛽 (10−9M)were significantly reduced following the addition of peptide (1000𝜇g/mL) compared to the no peptide controls
(∗∗𝑃 < 0.05) (𝑛 = 3, mean ± sd).
cells and the presence of IL-1 receptor on keratocytes in the
underlying stroma [42]. Thus, any breakdown of the corneal
surface or penetrating injury to the cornea results in the
release of IL-1 and subsequent proinflammatory signalling
and upregulation of IL-6, IL-8, and more IL-1 in underlying
keratocytes [43, 44]. In cases of LSCD, patients often present
with persistent epithelial breakdown and chronic stromal
inflammation [11, 45], associated with the recruitment of
elevated numbers of leukocytes to the normally immune
privileged cornea [12, 46]. This influx of leukocytes has been
linked to increased possibility of rejection of allografts used
to repair the damaged cornea [47]. Therefore, a reduction in
proinflammatory IL-1 signalling may improve management
and control of corneal inflammation and result in improved
graft survival. The use of recombinant IL-1ra has previously
been investigated as a possible means of attenuating IL-
1 signalling in the cornea [48, 49]. However, recombinant
proteins have prohibitive costs [50] and are less able to bind
to surfaces in conformationally active form because of their
size. As a result we have chosen to investigate the use of short
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Figure 7: IL-1𝛽 gene expression in LPS stimulated keratocytes treated with peptide was compared to LPS stimulated, nonpeptide treated, and
non-LPS stimulated controls using q-PCR. Relative genetic expression of IL-1𝛽 was compared to expression of the GAPDH housekeeping
gene. Keratocytes stimulated with LPS demonstrated a significant increase in IL-1𝛽 gene expression compared to the non-LPS stimulated
control. The addition of 1000 𝜇g/mL peptide significantly reduced IL-1𝛽 expression to that of the non-LPS stimulated control (∗∗𝑃 < 0.05)
(𝑛 = 3, mean ± sd).
(a) (b)
Figure 8: Immunocytochemical staining of TLR4 in (a) nonpermeabilized keratocytes and (b) permeabilized keratocytes (mag ×200) No
TLR4 was detected in LESCs (data not shown).
amino acid chain peptides tomimic the function of IL-1ra and
assess the feasibility of combining this peptide with a contact
lens carrier.
A 21 amino acid peptide IL-1ra analogue, based on the
work of Yanofsky et al. andVigers et al. [31, 32], was produced
and tested for potential anti-inflammatory properties using
an in vitromodel of corneal inflammation. The long primary
structure of the peptide increases the risk of improper
structural folding and mismatching of amino acids during
production. However by application of repeated coupling
steps for each amino acid in the peptide sequence during
production, the peptide was successfully synthesised with
a purity of 88% as shown by HPLC. Potential peptide
toxicity was measured by standard MTS and LDH assays
since peptide synthesis involves reagents that may be toxic
[51]. Toxicity can cause side effects such as corneal melting
similar to that seen in treatment with NSAIDs [52] and
inflammatory stimulants may induce cytotoxic effects [53].
The peptide was not cytotoxic to keratocytes up to the highest
test concentration of 1mg/mL.
We first tested our model of corneal inflammation. A
minimum concentration of 0.02 𝜇g/mL LPS was required
to induce measurable cytokine production by keratocytes
following 24 hours of incubation. This time period was
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(a) (b)
Figure 9: Functionalization of the silicone hydrogel contact lenses: (a) methyl orange assay of APTES treated (top) and untreated (bottom)
lenses showing the presence of NH
2
groups in the APTES treated lens and (b) BCA assay of peptide treated (top) and untreated (bottom)
lenses showing the presence of peptide on the top lens.
(a)
(b)
Figure 10: Immunocytochemical K3, K19, and p63 staining of primary LESC cultures cultured on (a) glass coverslips and (b) functionalised
contact lenses. All corneal epithelial cells and putative LESC markers (K3, K19, and p63) were present indicating the presence of limbal
epithelial cells on the functionalised contact lens. The curve of the contact lens can be seen for images in (b). The tightly packed, cobblestone
morphology characteristic of epithelial cells can be observed following cytoskeletal staining with phalloidin. Cell nuclei were stained with
DAPI (Leica confocal microscope, mag ×200).
selected based on work by Shtein et al. suggesting that
keratocyte cytokine production is optimal following LPS
stimulation over 24 hours [47].
Contrary to work published by others, LPS stimulation
did not result in cytokine production by LESC, despite
utilising the same source of LPS as previously reported [54–
58].
LPS induces downstream signalling and inflammation
in cells through binding to toll-like receptors (TLRs), espe-
cially TLR4 [59]. TLR4 has been reported to be absent
from the plasma membrane of epithelial cells, where it is
expressed only intracellularly [59, 60]. In our study, TLR4
was indeed absent from the plasma membrane of LESC.
This is perhaps not surprising, as the corneal epithelium
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acts as an external barrier to the outside environment and
is thus regularly exposed to environmental pathogens. An
inflammatory response to regular contact with bacterial-
derived LPSmay therefore be unnecessary and inappropriate.
When damage to the surface of the cornea occurs and such
environmental pathogen products are able to enter the cells,
activation of intracellular pathways to inflammation occurs.
The LESC strains used in our study were derived from at
least 3 different donors for the experiments to allow for donor
variability in LPS response. Our data showing the absence of
TLR expression in the LESCs explains the absence of cytokine
response to LPS.
LPS was able to stimulate IL-8 and IL-6 production,
but IL-1𝛽 was only measurably increased at the mRNA
level (𝑃 < 0.01). The results indicate that keratocytes do
upregulate IL-1𝛽 gene expression upon LPS stimulation but
may require further stimulants for translation and secretion
or may require a longer time frame.
In addition to LPS, we tested the ability of IL-1𝛽 to stimu-
late inflammatory cytokine production in our inflammatory
model. IL-1𝛽 was able to stimulate significant production of
IL-8, IL-6, and IL-1𝛽 in both cell types. We next tested the
ability of the recombinant peptide to reduce proinflammatory
signalling in our model.
A peptide concentration of 1mg/mL was able to signifi-
cantly reduce the release of IL-8 and IL-6 from keratocytes
stimulated with LPS. Furthermore, the same concentration
of peptide was able to suppress IL-1𝛽 gene expression.
When keratocytes and LESCs were stimulated with IL-1𝛽, the
peptide was shown to significantly reduce the release of IL-8
and IL-6 in both cell types and IL-1𝛽 in LESC.The response in
keratocytes was variable which is likely due to the autocrine
feedback signalling loop in these cells which results in IL-1𝛽
upregulation [36–38].
LSCD can occur when insult to the cornea penetrates
the epithelial layers to the underlying stroma, allowing IL-
1𝛽 released by epithelial cells to subsequently stimulate
keratocytes in the stroma promoting inflammation, through
inflammatory mediators IL-8 and IL-6. Reduction of these
cytokines on peptide addition suggests that peptide use may
lead to a reduction in inflammation and improved integration
of allografts used to repopulate the corneal surface.
Communication between cells in the stromal and epithe-
lial layers and a balanced inflammatory response is important
in wound healing [36, 37, 61]. For example, IL-1𝛽 stimulation
of keratocytes results in upregulation ofHGF andKGF, which
has been shown to improve reepithelialisation [62–64]. The
peptide utilised in this study reduced inflammatory cytokine
release by both keratocytes and LESC significantly.However,
measurable levels of cytokine were present indicating a base-
line inflammatory response in the presence of peptide but
the potential to suppress the peaks of excessive inflammatory
cytokine production during chronic inflammation.
In order to develop a delivery system suitable for clinical
application, LESCs were grown on a carrier, which was
functionalised with the peptide. Bausch & Lomb PureVi-
sion (balafilcon A) contact lenses were used since they are
already approved for 30-day extended wear and therapeutic
use, allowing sufficient time for the transplanted LESC to
repopulate the epithelial surface. Contact lenses have previ-
ously been used in ocular surface reconstruction. Di Giro-
lamo et al. [65] cultured corneal cells directly onto a contact
lens for patients to wear for a time period of between 14
and 22 days. Successful reestablishment of the ocular surface
was demonstrated following 13 months postsurgical follow-
up. When amnion is utilised as a carrier, an average time of
22.8 days has been reported to treat partial LSCD [66]. These
studies suggest that 30-day continuous wear will provide a
sufficient timeframe for LSCD treatment. Functionalization
of the lens, by establishing amine groups to facilitate peptide
binding, resulted in successful binding of 2.7 nmol peptide
to the inner surface and successful growth of LESC sheets
on the surface of the lens. Results suggest that a surface
functionalised peptide or eluted peptide fraction could be
used to effectively mimic the anti-inflammatory function
of amniotic membrane in part by reducing IL-1 proinflam-
matory signalling in order to improve graft integration and
clinical outcome.
5. Conclusion
Whilst the role of topical Il-1𝛽 antagonist has previously been
demonstrated in the control of corneal inflammation, our
work is the first to synthesise and characterise a short chain
IL-1 receptor antagonist peptide for this application using
isolated corneal cell cultures to assess peptide suppression of
inflammatory pathways and a functionalised silicon hydrogel
carrier to assess the effect of peptide coating on corneal
epithelial stem cell growth. Use of a short chain peptide
rather than full length protein is cost-effective and improves
conformational binding of active peptide to a carrier surface.
The peptide suppressed TLR4 mediated LPS stimulation
of cytokine production in keratocytes and IL1𝛽 stimulated
cytokine production in limbal epithelial stem cells and
keratocytes. Peptide coated silicon hydrogels were able to
maintain limbal epithelial stem cell fraction and support
epithelial sheet growth. The peptide may be used to augment
corneal epithelial sheet delivery for grafting and to control
excessive inflammation which limits current grafting success.
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